Geneuro SA (GNRO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Geneuro SA (GNRO) has a cash flow conversion efficiency ratio of 0.393x as of December 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-5.42 Million ≈ $-6.34 Million USD) by net assets (€-13.78 Million ≈ $-16.11 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see GNRO market cap for the company's overall valuation and market capitalisation.
Geneuro SA - Cash Flow Conversion Efficiency Trend (2012–2023)
This chart illustrates how Geneuro SA's cash flow conversion efficiency has evolved over time, based on yearly financial data. View GNRO stock price for real-time trading data and today's change.
Geneuro SA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Geneuro SA ranked by their cash flow conversion efficiency. Review free cash flow generation of Geneuro SA to assess how much free cash flow the company generates relative to operating cash flow.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ampli SA w upadlosci ukladowej
WAR:APL
|
0.049x |
|
The Hydration Pharmaceuticals Company Ltd
AU:HPC
|
-0.606x |
|
Aker Horizons AS
OL:AKH
|
-0.007x |
|
SPOTLITE360 IOT SOLUTIONS
F:87A0
|
N/A |
|
FKS Food Sejahtera Tbk PT
JK:AISA
|
0.005x |
|
Teras Resources Inc
V:TRA
|
0.129x |
|
BEACN Wizardry & Magic Inc
V:BECN
|
0.886x |
|
Migo Opportunities Trust PLC
LSE:MIGO
|
-0.009x |
Annual Cash Flow Conversion Efficiency for Geneuro SA (2012–2023)
The table below shows the annual cash flow conversion efficiency of Geneuro SA from 2012 to 2023. Also see Geneuro SA asset portfolio for a full breakdown of the balance sheet.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-12-31 | €-13.78 Million ≈ $-16.11 Million |
€-10.15 Million ≈ $-11.86 Million |
0.736x | +107.96% |
| 2022-12-31 | €1.41 Million ≈ $1.65 Million |
€-13.07 Million ≈ $-15.28 Million |
-9.250x | -544.37% |
| 2021-12-31 | €4.73 Million ≈ $5.53 Million |
€-6.78 Million ≈ $-7.93 Million |
-1.435x | -8.85% |
| 2020-12-31 | €5.44 Million ≈ $6.36 Million |
€-7.17 Million ≈ $-8.39 Million |
-1.319x | -169.00% |
| 2019-12-31 | €-5.31 Million ≈ $-6.20 Million |
€-10.14 Million ≈ $-11.86 Million |
1.911x | +160.56% |
| 2018-12-31 | €5.55K ≈ $6.49K |
€-17.53K ≈ $-20.49K |
-3.156x | -438.95% |
| 2017-12-31 | €13.06K ≈ $15.27K |
€-7.65K ≈ $-8.94K |
-0.586x | +22.96% |
| 2016-12-31 | €18.67K ≈ $21.82K |
€-14.19K ≈ $-16.59K |
-0.760x | -110.87% |
| 2015-12-31 | €1.69K ≈ $1.98K |
€11.84K ≈ $13.84K |
6.989x | +1378.93% |
| 2014-12-31 | €6.24 Million ≈ $7.30 Million |
€2.95 Million ≈ $3.45 Million |
0.473x | +137.32% |
| 2013-12-31 | €2.71 Million ≈ $3.17 Million |
€-3.43 Million ≈ $-4.01 Million |
-1.266x | -102.91% |
| 2012-12-31 | €-62.50K ≈ $-73.07K |
€-2.72 Million ≈ $-3.18 Million |
43.554x | -- |
About Geneuro SA
GeNeuro SA, a clinical-stage biopharmaceutical company, develops drugs for the treatment of neurodegenerative and autoimmune diseases. The company's lead therapeutic candidate is temelimab, a monoclonal antibody that neutralizes a pathogenic protein of the HERV-W family that has completed a Phase II clinical trials. It is also developing GNC-501 for post-COVID on patients with persistent neuropsy… Read more